OBI Pharma, Inc. (TPEX:4174)
Taiwan · Delayed Price · Currency is TWD 25.55
-0.75 (-2.85%)
Jul 29, 2026, 1:30 PM CST
OBI Pharma Financials Overview
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 49.68 | 58.58 | 62.68 | 41.55 | 4.71 | 18.77 |
Revenue Growth | -26.94% | -6.55% | 50.85% | 781.96% | -74.90% | -86.68% |
Gross Profit Gross Profit Growth | -89.02 | -77.53 | -76.27 | -73.5 | -40.14 | -25.59 |
Operating Income Operating Income Growth | -2,112 | -2,169 | -2,372 | -2,090 | -2,123 | -1,716 |
Net Income Net Income Growth | -1,982 | -2,053 | -2,310 | -1,046 | -1,614 | -1,531 |
Earnings Per Share EPS Growth | -15.07 | -15.61 | -19.78 | -9.14 | -14.53 | -15.39 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Adjustments and Eliminations Adjustments and Eliminations Growth | -12.76 | -19.27 | -28.1 | -29.31 | -59.79 | -24.79 |
CDMO CDMO Growth | 53.93 | 69.27 | 87.41 | 68.83 | 62.5 | 34.81 |
New Anticancer Drug New Anticancer Drug Growth | 8.52 | 8.57 | 3.37 | 2.03 | 2 | 1.76 |
Total Total Growth | 49.68 | 58.58 | 62.68 | 41.55 | 4.71 | 18.77 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 802.32 | 1,186 | 3,131 | 2,782 | 4,773 | 2,654 |
Total Debt Total Debt Growth | 461.79 | 515.68 | 504.63 | 547.11 | 293.15 | 293.03 |
Net Cash (Debt) Net Cash Growth | 340.53 | 670.65 | 2,626 | 2,235 | 4,479 | 2,361 |
Net Cash Growth | -82.49% | -74.46% | 17.49% | -50.10% | 89.73% | -32.08% |
Net Cash Per Share Net Cash Per Share Growth | 2.59 | 5.10 | 22.48 | 19.52 | 40.33 | 23.73 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -1,709 | -2,020 | -1,834 | -1,653 | -1,620 | -1,064 |
Capital Expenditures CapEx Growth | -31.81 | -43.87 | -113.24 | -101.93 | -254.65 | -241.33 |
Free Cash Flow Free Cash Flow Growth | -1,741 | -2,064 | -1,947 | -1,755 | -1,874 | -1,306 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | -179.19% | -132.36% | -121.69% | -176.89% | - | -136.32% |
Operating Margin | -4250.69% | -3702.58% | -3783.67% | -5029.70% | -45059.69% | -9141.35% |
Pretax Margin | -4451.32% | -3857.41% | -3982.59% | -3070.00% | -40693.95% | -9281.13% |
Profit Margin | -3988.99% | -3504.61% | -3685.54% | -2518.65% | -34258.46% | -8154.10% |
FCF Margin | -3504.03% | -3523.70% | -3105.95% | -4223.71% | -39786.71% | -6956.13% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | - | 212.73 | 212.73 | 212.73 | 212.73 | 212.73 |
PS Ratio | 67.67 | 121.22 | 245.51 | 382.92 | 3360.52 | 1208.19 |